Lido Advisors’s Tandem Diabetes Care TNDM Stock Holding History

Lido Advisors’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,515	Closed	-$228K	–	1091
2021 Q4	$228K	Buy	+1,515	New	+$204K	﹤0.01%	919

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Lido Advisors's TNDM Position: Q1 2022 in Review

Lido Advisors sold out of Tandem Diabetes Care (TNDM) in Q1 2022, closing a stake of 1,515 shares — an estimated $228K sold.

Lido Advisors first reported a position in TNDM in Q4 2021 and held it in 1 quarter. The position peaked at $228K in Q4 2021. 379 funds tracked by Wall St. Rank hold TNDM as of Q1 2022.

Lido Advisors reported no remaining Tandem Diabetes Care position as of Q1 2022 after selling out during the quarter.
Lido Advisors sold 1,515 Tandem Diabetes Care shares in Q1 2022, an estimated $228K.
Lido Advisors first reported a position in Tandem Diabetes Care in Q4 2021 and held it in 1 quarter.
Lido Advisors's Tandem Diabetes Care position peaked at $228K in Q4 2021.
379 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2022.

Based on Lido Advisors's 13F filing for Q1 2022, filed 17 May 2022.